Table 2.

TRAEs

	Patients (n = 20)
Any Grade TRAEs, No. (%)	20 (100.0)
Grade ≥ 3	7 (35.0)
Treatment suspension	4 (20.0)
Dose reduction	3 (15.0)
Death	0
Incidence rate	Any Grade	Grade ≥ 3
HFSR	5 (25.0)	1 (5.0)
Rash	4 (20.0)	0
Pruritus	3 (15.0)	0
Diarrhea	6 (30.0)	0
Bloating	4 (20.0)	0
Constipation	2 (10.0)	0
Ileus	3 (15.0)	0
Hypothyroidism	8 (40.0)	1 (5.0)
Hyperthyroidism	1 (5.0)	0
Liver dysfunction	5 (25.0)	1 (5.0)
Hypertension	7 (35.0)	1 (5.0)
Hyperglycemia	4 (20.0)	1 (5.0)
Weight loss	5 (25.0)	0
Fatigue	11 (55.0)	0
Decreased appetite	13 (65.0)	0
Hoarseness	9 (45.0)	0
Dry mouth	5 (25.0)	0
Mucositis oral	3 (15.0)	0
Periodontal disease	3 (15.0)	0
Epistaxis	8 (40.0)	0
FOBT positive	12 (60.0)	2 (10.0)
Albuminuria	13 (65.0)	3 (15.0)
Urine occult blood	7 (35.0)	2 (10.0)
Fever	3 (15.0)	0
Leukopenia	3 (15.0)	0
Thrombocytopenia	2 (10.0)	0
Hypoalbuminemia	2 (10.0)	0
Anemia	3 (15.0)	0
Hypokalemia	3 (15.0)	0
Hyponatremia	1 (5.0)	0
Headache	4 (20.0)	0
Musculoskeletal pain	2 (10.0)	0
Visual fatigue	1 (5.0)	0
Insomnia	3 (15.0)	0
Hypomnesis	1 (5.0)	0
Nausea	2 (10.0)	0
Vomiting	1 (5.0)	0
Cough	2 (10.0)	0

Abbreviations: TRAEs, treatment-related adverse events; HFSR, hand-foot skin reaction; FOBT, fecal occult blood test.